Details of Disease

General Information of Disease (ID: DISRTNTN)

Disease Name Urothelial carcinoma
Synonyms Uroepithelial carcinoma; transitional cell car. -uroth.; transitional cell carcinoma of the urinary tract; transitional cell carcinoma of the urothelial tract; urothelial carcinoma
Disease Class 2C92: Ureteral cancer
Definition A malignant neoplasm derived from the transitional epithelium of the urinary tract (urinary bladder, ureter, urethra, or renal pelvis). It is frequently papillary.
Disease Hierarchy
DISQ27NU: Urothelial neoplasm
DISDQ6PK: Malignant urinary system neoplasm
DISWVVDR: Transitional cell carcinoma
DISRTNTN: Urothelial carcinoma
ICD Code
ICD-11
ICD-11: 2C92.0
Disease Identifiers
MONDO ID
MONDO_0040679
UMLS CUI
C2145472
MedGen ID
760495

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 9 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Atezolizumab DMMF8U0 Approved Monoclonal antibody [1]
Bavencio DMU9C8F Approved Monoclonal antibody [1]
Durvalumab DM4PVDY Approved Monoclonal antibody [2]
Enfortumab DMFS63G Approved Antibody drug conjugate [3]
Enfortumab vedotin DMW5V4U Approved Antibody drug conjugate [4]
Erdafitinib DMI782S Approved NA [1]
RG-7446 DM69XMQ Approved Monoclonal antibody [5]
Sacituzumab govitecan DMUWFD8 Approved Antibody drug conjugate [6]
Toripalimab DMSGA6Z Approved in China Monoclonal antibody [7]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 Drug(s)
This Disease is Treated as An Indication in 11 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Cotellic DMF9M57 Phase 3 Small molecular drug [1]
INCB24360 DMIJGT9 Phase 3 Small molecular drug [8]
B-701 DMOMDA4 Phase 2 NA [9]
DS-3201b DMI69E5 Phase 2 Small molecular drug [10]
MRG002 DMJK8L1 Phase 2 Antibody drug conjugate [11]
MV-NIS DMGOLCU Phase 2 Oncolytic virus therapy [12]
RG7888 DM2SWI8 Phase 2 Antibody [9]
TEW-7197 DM2LBC3 Phase 2 NA [13]
ASG-15ME DMM9ORD Phase 1 Antibody [9]
IK-175 DMDU54Y Phase 1 Small molecular drug [14]
VAX014 DMZK16N Phase 1 NA [15]
------------------------------------------------------------------------------------
⏷ Show the Full List of 11 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 37 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
KCNN3 TT9JH25 Limited Biomarker [16]
HRAS TT28ZON Disputed Biomarker [17]
GRIK2 TT0K5RG moderate Biomarker [18]
PRAME TTPH7T0 moderate Altered Expression [19]
ANXA10 TT0NL6U Strong Biomarker [20]
BST2 TT90BJT Strong Biomarker [21]
CASP4 TT6KIOT Strong Biomarker [22]
CBX7 TTBN3HC Strong Biomarker [23]
CCNE1 TTCEJ4F Strong Biomarker [24]
DEPDC1 TT8S9CM Strong Biomarker [25]
DHCR24 TTTK0NH Strong Genetic Variation [26]
EIF5A2 TTH53G9 Strong Biomarker [27]
FABP2 TTS4YLO Strong Biomarker [28]
FGFR3 TTST7KB Strong Genetic Variation [29]
GFRA3 TT63XRS Strong Altered Expression [30]
GPR87 TTO897C Strong Biomarker [31]
GSTO1 TTWO3SH Strong Genetic Variation [32]
HDAC8 TTT6LFV Strong Biomarker [33]
HOXB13 TTZ6I58 Strong Biomarker [34]
IMP3 TTEJA2R Strong Altered Expression [35]
INHBA TTVB30D Strong Altered Expression [36]
KIF20B TTQECT2 Strong Biomarker [25]
KRT17 TTKV0EC Strong Biomarker [37]
MAGEC2 TTKGUEB Strong Altered Expression [19]
MKI67 TTB4UNG Strong Biomarker [38]
MLH1 TTISG27 Strong Biomarker [39]
NACC1 TT4AQ5F Strong Altered Expression [40]
NCOA3 TT124R0 Strong Altered Expression [41]
NECTIN4 TTPO9EG Strong Biomarker [42]
PDCD1LG2 TTW14O3 Strong Biomarker [43]
RECK TTRZBW7 Strong Altered Expression [44]
SLITRK6 TTTVEKI Strong Biomarker [42]
TLR6 TTWRI8V Strong Altered Expression [45]
TRPV2 TTBECWA Strong Altered Expression [46]
DDR2 TTU98HG Definitive Altered Expression [47]
PINX1 TT4FJ3A Definitive Biomarker [48]
RSF1 TTMP86V Definitive Biomarker [49]
------------------------------------------------------------------------------------
⏷ Show the Full List of 37 DTT(s)
This Disease Is Related to 3 DME Molecule(s)
Gene Name DME ID Evidence Level Mode of Inheritance REF
CYP2A13 DEXZA9U Strong Genetic Variation [50]
GSTO2 DEHMPZR Strong Genetic Variation [51]
UGT2B7 DEB3CV1 Strong Genetic Variation [50]
------------------------------------------------------------------------------------
This Disease Is Related to 71 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
TOMM34 OTH6MITE Limited Altered Expression [52]
DEDD OTIL349E moderate Biomarker [53]
SPARCL1 OT74DWMV moderate Posttranslational Modification [54]
TNFAIP6 OT1SLUZH moderate Biomarker [55]
ALKBH2 OTSQW0BG Strong Biomarker [56]
ALKBH3 OTS1CD9Z Strong Altered Expression [57]
ANKRD36B OT3MW415 Strong Biomarker [58]
ARIH1 OTO3XDR2 Strong Biomarker [59]
BCAM OTHZOPSD Strong Biomarker [60]
BOK OTDQPDIX Strong Biomarker [61]
BRINP1 OTEUVSCP Strong Genetic Variation [62]
CBX8 OT4U5V1T Strong Biomarker [63]
CCAR2 OTLUDG5T Strong Genetic Variation [62]
CDC42EP3 OTUZ3U9Z Strong Biomarker [64]
CEBPD OTNBIPMY Strong Biomarker [65]
CKS1B OTNUPLUJ Strong Biomarker [66]
CMAS OTFQJG3C Strong Biomarker [67]
CSTF2 OTR6G4II Strong Biomarker [68]
CTNNA3 OT9Z0P1E Strong Altered Expression [69]
CUL1 OTXPE1UZ Strong Altered Expression [70]
DAB2 OTRMQTMZ Strong Altered Expression [71]
DAB2IP OTF456VC Strong Altered Expression [72]
DACH2 OT33KEUZ Strong Biomarker [73]
DOC2A OT5G9V94 Strong Altered Expression [71]
EFNA1 OTU2NUA2 Strong Biomarker [74]
ELAVL3 OTI2VI8B Strong Altered Expression [75]
EMP2 OTPS2H0L Strong Biomarker [76]
EMP3 OTODMJ1D Strong Altered Expression [77]
FOXA1 OTEBY0TD Strong Biomarker [78]
GAB1 OTQKE6V4 Strong Biomarker [79]
GLS2 OT08MSHL Strong Altered Expression [80]
GPX2 OTXI2NTI Strong Altered Expression [81]
HAS3 OTPM8IL8 Strong Altered Expression [82]
HEPACAM OT1MJ51D Strong Biomarker [83]
IFNA17 OTHXRYG3 Strong Biomarker [84]
IFNL2 OT4BMJF7 Strong Altered Expression [85]
KAT2A OTN0W2SW Strong Genetic Variation [86]
KCNK17 OTG2NEZM Strong Biomarker [87]
KPNA2 OTU7FOE6 Strong Altered Expression [88]
KRT20 OT4RB40L Strong Biomarker [89]
LARGE2 OT5BZS3J Strong Biomarker [90]
LGALS4 OTKQCG0H Strong Biomarker [91]
MCM10 OTV0O3JN Strong Biomarker [92]
MIB1 OT5C404P Strong Biomarker [93]
MMD OTB5I4OC Strong Biomarker [94]
MMUT OTBBBV70 Strong Biomarker [95]
NAIP OTLA925F Strong Biomarker [96]
NDN OTYBYJ82 Strong Biomarker [97]
NID2 OTHC33FF Strong Posttranslational Modification [98]
NLRP4 OT864X7M Strong Biomarker [96]
NLRP9 OTUZVWHM Strong Biomarker [96]
NME5 OTE8OLFN Strong Altered Expression [99]
NUMA1 OTTKAVG4 Strong Biomarker [100]
PIAS1 OTZVAHZI Strong Biomarker [101]
PLEK OTB73XXA Strong Genetic Variation [102]
PPL OTTM4WDO Strong Altered Expression [103]
PTOV1 OT94WT5X Strong Altered Expression [104]
RING1 OTCWTAX0 Strong Biomarker [105]
RNF2 OTFPLOIN Strong Altered Expression [106]
RRM2B OTE8GBUR Strong Genetic Variation [107]
SFXN1 OTL66767 Strong Biomarker [108]
SH3BGRL3 OTKMW34I Strong Biomarker [109]
SH3GL2 OTOE443G Strong Altered Expression [110]
STAG2 OTR6X1Q7 Strong Genetic Variation [111]
TARBP2 OT1QQ8H3 Strong Genetic Variation [112]
TGFBI OTR443C5 Strong Biomarker [113]
TLR10 OTQ1KVJO Strong Altered Expression [114]
TMEM67 OTME92T5 Strong Altered Expression [115]
TMX1 OTX4FHYQ Strong Biomarker [116]
TNFAIP2 OTRZH80H Strong Altered Expression [117]
SULF1 OTJCNCO0 Definitive Biomarker [118]
------------------------------------------------------------------------------------
⏷ Show the Full List of 71 DOT(s)

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2018
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
4 FDA Approved Drug Products from FDA Official Website.
5 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
6 FDA Approved Drug Products from FDA Official Website.
7 Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China. Front Immunol. 2022 Jan 12;12:730666.
8 ClinicalTrials.gov (NCT03361865) Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307). U.S. National Institutes of Health.
9 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10 ClinicalTrials.gov (NCT04388852) DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers. U.S. National Institutes of Health.
11 ClinicalTrials.gov (NCT04839510) A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer. U.S. National Institutes of Health.
12 ClinicalTrials.gov (NCT03171493) Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical Cystectomy. U.S. National Institutes of Health.
13 ClinicalTrials.gov (NCT04064190) Vactosertib With Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition. U.S. National Institutes of Health.
14 ClinicalTrials.gov (NCT04200963) A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma. U.S. National Institutes of Health.
15 ClinicalTrials.gov (NCT03854721) A Phase 1 Study of Intravesical VAX014 for Instillation in Subjects With Non-Muscle Invasive Bladder Cancer. U.S. National Institutes of Health.
16 The small conductance calcium-activated potassium channel 3 (SK3) is a molecular target for Edelfosine to reduce the invasive potential of urothelial carcinoma cells.Tumour Biol. 2016 May;37(5):6275-83. doi: 10.1007/s13277-015-4509-5. Epub 2015 Nov 30.
17 Carbonic anhydrase 2 is a novel invasion-associated factor in urinary bladder cancers.Cancer Sci. 2017 Mar;108(3):331-337. doi: 10.1111/cas.13143.
18 GRIK2 has a role in the maintenance of urothelial carcinoma stem-like cells, and its expression is associated with poorer prognosis.Oncotarget. 2017 Apr 25;8(17):28826-28839. doi: 10.18632/oncotarget.16259.
19 Evaluation of cancer testis antigen (CT10, PRAME) and MHC I expression in high-grade urothelial carcinoma of the bladder.Virchows Arch. 2020 Apr;476(4):535-542. doi: 10.1007/s00428-019-02661-2. Epub 2019 Sep 2.
20 Identification of Downstream Genes of the mTOR Pathway that Predict Recurrence and Progression in Non-Muscle Invasive High-Grade Urothelial Carcinoma of the Bladder.J Korean Med Sci. 2017 Aug;32(8):1327-1336. doi: 10.3346/jkms.2017.32.8.1327.
21 Overexpression of the transmembrane protein BST-2 induces Akt and Erk phosphorylation in bladder cancer.Oncol Lett. 2017 Jul;14(1):999-1004. doi: 10.3892/ol.2017.6230. Epub 2017 May 23.
22 Down-regulation of glucose-regulated protein (GRP) 78 potentiates cytotoxic effect of celecoxib in human urothelial carcinoma cells.PLoS One. 2012;7(3):e33615. doi: 10.1371/journal.pone.0033615. Epub 2012 Mar 16.
23 Expression parameters of the polycomb group proteins BMI1, SUZ12, RING1 and CBX7 in urothelial carcinoma of the bladder and their prognostic relevance.Tumour Biol. 2008;29(5):323-9. doi: 10.1159/000170879. Epub 2008 Nov 5.
24 Target genes of recurrent chromosomal amplification and deletion in urothelial carcinoma.Cancer Genomics Proteomics. 2014 May-Jun;11(3):141-53.
25 A phase I/II study of cancer peptide vaccine S-288310 in patients with advanced urothelial carcinoma of the bladder.Ann Oncol. 2017 Apr 1;28(4):798-803. doi: 10.1093/annonc/mdw675.
26 Dynamic Contrast-enhanced MRI in Renal Tumors: Common Subtype Differentiation using Pharmacokinetics.Sci Rep. 2017 Jun 8;7(1):3117. doi: 10.1038/s41598-017-03376-7.
27 Overexpression of EIF5A2 in upper urinary tract urothelial carcinoma is a new independent prognostic marker of survival.Future Oncol. 2019 Jun;15(17):2009-2018. doi: 10.2217/fon-2018-0748. Epub 2019 Apr 1.
28 The molecular signature for urothelial carcinoma of the upper urinary tract.J Urol. 2008 Mar;179(3):1155-9. doi: 10.1016/j.juro.2007.10.026.
29 ETV5 links the FGFR3 and Hippo signalling pathways in bladder cancer.Sci Rep. 2019 Apr 5;9(1):5740. doi: 10.1038/s41598-018-36456-3.
30 Expression of GFR3 correlates with tumor progression and promotes cell metastasis in urothelial carcinoma.Minerva Urol Nefrol. 2018 Feb;70(1):79-86. doi: 10.23736/S0393-2249.17.02887-9. Epub 2017 Jun 23.
31 Expression and role of GPR87 in urothelial carcinoma of the bladder.Int J Mol Sci. 2013 Jun 10;14(6):12367-79. doi: 10.3390/ijms140612367.
32 Combined effects of GSTO1 and SULT1A1 polymorphisms and cigarette smoking on urothelial carcinoma risk in a Taiwanese population.J Formos Med Assoc. 2014 Sep;113(9):640-7. doi: 10.1016/j.jfma.2012.08.015. Epub 2012 Sep 23.
33 HDACs and HDAC Inhibitors in Urothelial Carcinoma - Perspectives for an Antineoplastic Treatment.Curr Med Chem. 2017;24(37):4151-4165. doi: 10.2174/0929867324666170207142740.
34 HOXB13 as an immunohistochemical marker of prostatic origin in metastatic tumors.APMIS. 2016 Mar;124(3):188-93. doi: 10.1111/apm.12483. Epub 2015 Nov 20.
35 IMP3 is a biomarker for non-muscle-invasive urothelial carcinoma of the bladder associated with an aggressive phenotype.Medicine (Baltimore). 2019 Jul;98(27):e16009. doi: 10.1097/MD.0000000000016009.
36 INHBA overexpression indicates poor prognosis in urothelial carcinoma of urinary bladder and upper tract.J Surg Oncol. 2015 Mar 15;111(4):414-22. doi: 10.1002/jso.23836. Epub 2014 Dec 9.
37 Keratin 17 is a sensitive and specific biomarker of urothelial neoplasia.Mod Pathol. 2019 May;32(5):717-724. doi: 10.1038/s41379-018-0177-5. Epub 2018 Nov 15.
38 Predictive value of lymphangiogenesis and proliferation markers on mRNA level in urothelial carcinoma of the bladder after radical cystectomy.Urol Oncol. 2018 Dec;36(12):530.e19-530.e27. doi: 10.1016/j.urolonc.2018.09.003. Epub 2018 Nov 13.
39 Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma.Genet Med. 2020 Apr;22(4):709-718. doi: 10.1038/s41436-019-0720-x. Epub 2019 Dec 17.
40 NACC1, as a Target of MicroRNA-331-3p, Regulates Cell Proliferation in Urothelial Carcinoma Cells.Cancers (Basel). 2018 Sep 21;10(10):347. doi: 10.3390/cancers10100347.
41 Impact of AIB1 expression on the prognosis of upper tract urothelial carcinoma after radical nephroureterectomy.Cancer Biomark. 2019;25(2):151-160. doi: 10.3233/CBM-182020.
42 Targeting advanced urothelial carcinoma-developing strategies.Curr Opin Oncol. 2019 May;31(3):207-215. doi: 10.1097/CCO.0000000000000532.
43 The correlation of BER protein, IRF3 with CD8+ T cell and their prognostic significance in upper tract urothelial carcinoma.Onco Targets Ther. 2019 Sep 24;12:7725-7735. doi: 10.2147/OTT.S222422. eCollection 2019.
44 Effects of DNMT and MEK inhibitors on the expression of RECK, MMP-9, -2, uPA and VEGF in response to arsenite stimulation in human uroepithelial cells.Toxicol Lett. 2011 Feb 25;201(1):62-71. doi: 10.1016/j.toxlet.2010.12.006. Epub 2010 Dec 15.
45 Toll-like receptor 6 and connective tissue growth factor are significantly upregulated in mitomycin-C-treated urothelial carcinoma cells under hydrostatic pressure stimulation.Genet Test Mol Biomarkers. 2014 Jun;18(6):410-6. doi: 10.1089/gtmb.2013.0443. Epub 2014 Apr 1.
46 Transient receptor potential vanilloid type 2 (TRPV2) expression in normal urothelium and in urothelial carcinoma of human bladder: correlation with the pathologic stage.Eur Urol. 2008 Sep;54(3):612-20. doi: 10.1016/j.eururo.2007.10.016. Epub 2007 Oct 16.
47 DDR2 overexpression in urothelial carcinoma indicates an unfavorable prognosis: a large cohort study.Oncotarget. 2016 Nov 29;7(48):78918-78931. doi: 10.18632/oncotarget.12912.
48 PinX1 suppresses bladder urothelial carcinoma cell proliferation via the inhibition of telomerase activity and p16/cyclin D1 pathway.Mol Cancer. 2013 Nov 23;12(1):148. doi: 10.1186/1476-4598-12-148.
49 Rsf-1/HBXAP overexpression is independent of gene amplification and is associated with poor outcome in patients with urinary bladder urothelial carcinoma.J Clin Pathol. 2012 Sep;65(9):802-7. doi: 10.1136/jclinpath-2012-200897. Epub 2012 Jun 9.
50 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism-related enzymes gene polymorphisms, NNK metabolites levels and urothelial carcinoma.Toxicol Lett. 2013 Jan 10;216(1):16-22. doi: 10.1016/j.toxlet.2012.11.002. Epub 2012 Nov 8.
51 Gene polymorphisms of glutathione S-transferase omega 1 and 2, urinary arsenic methylation profile and urothelial carcinoma.Sci Total Environ. 2011 Jan 1;409(3):465-70. doi: 10.1016/j.scitotenv.2010.10.053. Epub 2010 Nov 21.
52 Expression of TOMM34 and Its Clinicopathological Correlations in Urothelial Carcinoma of the Bladder.Pathol Oncol Res. 2020 Jan;26(1):411-418. doi: 10.1007/s12253-018-0524-3. Epub 2018 Oct 31.
53 MCL1 and DEDD Promote Urothelial Carcinoma Progression.Mol Cancer Res. 2019 Jun;17(6):1294-1304. doi: 10.1158/1541-7786.MCR-18-0963. Epub 2019 Feb 18.
54 Methylation of SPARCL1 Is Associated with Oncologic Outcome of Advanced Upper Urinary Tract Urothelial Carcinoma.Int J Mol Sci. 2019 Apr 3;20(7):1653. doi: 10.3390/ijms20071653.
55 High TNFAIP6 level is associated with poor prognosis of urothelial carcinomas.Urol Oncol. 2019 Apr;37(4):293.e11-293.e24. doi: 10.1016/j.urolonc.2018.12.009. Epub 2018 Dec 27.
56 ALKBH2, a novel AlkB homologue, contributes to human bladder cancer progression by regulating MUC1 expression.Cancer Sci. 2013 Mar;104(3):321-7. doi: 10.1111/cas.12089. Epub 2013 Feb 14.
57 ALKBH3 contributes to survival and angiogenesis of human urothelial carcinoma cells through NADPH oxidase and tweak/Fn14/VEGF signals.Clin Cancer Res. 2012 Oct 1;18(19):5247-55. doi: 10.1158/1078-0432.CCR-12-0955. Epub 2012 Jul 31.
58 Melanoma-associated antigen-A and programmed death-ligand 1 expression are associated with advanced urothelial carcinoma.Cancer Immunol Immunother. 2019 May;68(5):743-751. doi: 10.1007/s00262-019-02316-w. Epub 2019 Feb 21.
59 Receipt of 5-Alpha Reductase Inhibitors Before Radical Cystectomy: Do They Render High-Grade Bladder Tumors Less Aggressive?.Clin Genitourin Cancer. 2019 Dec;17(6):e1122-e1128. doi: 10.1016/j.clgc.2019.07.016. Epub 2019 Aug 5.
60 The role of Lutheran/basal cell adhesion molecule in human bladder carcinogenesis.J Biomed Sci. 2017 Aug 26;24(1):61. doi: 10.1186/s12929-017-0360-x.
61 Integrated genomic and transcriptional analysis of the in vitro evolution of telomerase-immortalized urothelial cells (TERT-NHUC).Genes Chromosomes Cancer. 2009 Aug;48(8):694-710. doi: 10.1002/gcc.20672.
62 Loss of heterozygosity at 9q32-33 (DBC1 locus) in primary non-invasive papillary urothelial neoplasm of low malignant potential and low-grade urothelial carcinoma of the bladder and their associated normal urothelium.J Pathol. 2008 Jul;215(3):263-72. doi: 10.1002/path.2353.
63 Chromobox homolog 8 is a predictor of muscle invasive bladder cancer and promotes cell proliferation by repressing the p53 pathway.Cancer Sci. 2017 Nov;108(11):2166-2175. doi: 10.1111/cas.13383. Epub 2017 Sep 25.
64 The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine.J Mol Diagn. 2000 Aug;2(3):116-23. doi: 10.1016/S1525-1578(10)60625-3.
65 MiR-193b Mediates CEBPD-Induced Cisplatin Sensitization Through Targeting ETS1 and Cyclin D1 in Human Urothelial Carcinoma Cells.J Cell Biochem. 2017 Jun;118(6):1563-1573. doi: 10.1002/jcb.25818. Epub 2016 Dec 20.
66 Increased SKP2 and CKS1 gene expression contributes to the progression of human urothelial carcinoma.J Urol. 2007 Jul;178(1):301-7. doi: 10.1016/j.juro.2007.03.002. Epub 2007 May 17.
67 The prognostic value of sarcopenia in patients with surgically treated urothelial carcinoma: A systematic review and meta-analysis.Eur J Surg Oncol. 2019 May;45(5):747-754. doi: 10.1016/j.ejso.2019.03.003. Epub 2019 Mar 7.
68 CSTF2-Induced Shortening of the RAC1 3'UTR Promotes the Pathogenesis of Urothelial Carcinoma of the Bladder.Cancer Res. 2018 Oct 15;78(20):5848-5862. doi: 10.1158/0008-5472.CAN-18-0822. Epub 2018 Aug 24.
69 Alpha-T-catenin (CTNNA3) displays tumour specific monoallelic expression in urothelial carcinoma of the bladder.Genes Chromosomes Cancer. 2007 Jun;46(6):587-93. doi: 10.1002/gcc.20443.
70 Expression of CUL1 correlates with tumour-grade and recurrence in urothelial carcinoma.ANZ J Surg. 2017 Jul;87(7-8):624-629. doi: 10.1111/ans.13438. Epub 2016 Jun 16.
71 Loss of DAB2IP expression in human urothelial carcinoma is associated with poorer recurrence-free survival.Virchows Arch. 2016 Jun;468(6):733-40. doi: 10.1007/s00428-016-1924-y. Epub 2016 Mar 22.
72 Low expression of DAB2IP predicts an unfavorable prognosis in human bladder carcinoma.Onco Targets Ther. 2017 Nov 29;10:5719-5726. doi: 10.2147/OTT.S146952. eCollection 2017.
73 Prospective validation of DACH2 as a novel biomarker for prediction of metastasis and prognosis in muscle-invasive urothelial carcinoma of the bladder.Biochem Biophys Res Commun. 2015 Apr 10;459(3):416-23. doi: 10.1016/j.bbrc.2015.02.119. Epub 2015 Mar 2.
74 Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder.Clin Cancer Res. 2006 Jan 15;12(2):353-60. doi: 10.1158/1078-0432.CCR-05-1505.
75 Expression of WWOX and FHIT is downregulated by exposure to arsenite in human uroepithelial cells.Toxicol Lett. 2013 Jul 4;220(2):118-25. doi: 10.1016/j.toxlet.2013.04.007. Epub 2013 Apr 22.
76 Epithelial membrane protein 2 is a prognostic indictor for patients with urothelial carcinoma of the upper urinary tract.Am J Pathol. 2013 Sep;183(3):709-19. doi: 10.1016/j.ajpath.2013.05.015. Epub 2013 Jul 6.
77 EMP1, EMP 2, and EMP3 as novel therapeutic targets in human cancer.Biochim Biophys Acta Rev Cancer. 2017 Aug;1868(1):199-211. doi: 10.1016/j.bbcan.2017.04.004. Epub 2017 Apr 10.
78 On a FOX hunt: functions of FOX transcriptional regulators in bladder cancer.Nat Rev Urol. 2017 Feb;14(2):98-106. doi: 10.1038/nrurol.2016.239. Epub 2016 Nov 29.
79 Gab1 is essential for membrane translocation, activity and integrity of mTORCs after EGF stimulation in urothelial cell carcinoma.Oncotarget. 2015 Jan 30;6(3):1478-89. doi: 10.18632/oncotarget.2756.
80 Long non-coding RNA UCA1 promotes glutamine metabolism by targeting miR-16 in human bladder cancer.Jpn J Clin Oncol. 2015 Nov;45(11):1055-63. doi: 10.1093/jjco/hyv132. Epub 2015 Sep 14.
81 GPX2 promotes development of bladder cancer with squamous cell differentiation through the control of apoptosis.Oncotarget. 2018 Mar 23;9(22):15847-15859. doi: 10.18632/oncotarget.24627. eCollection 2018 Mar 23.
82 HAS3 underexpression as an indicator of poor prognosis in patients with urothelial carcinoma of the upper urinary tract and urinary bladder.Tumour Biol. 2015 Jul;36(7):5441-50. doi: 10.1007/s13277-015-3210-z. Epub 2015 May 2.
83 Expression and clinical significance of hepaCAM and VEGF in urothelial carcinoma.World J Urol. 2010 Aug;28(4):473-8. doi: 10.1007/s00345-010-0573-z. Epub 2010 Jul 1.
84 Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma.Am J Pathol. 2005 May;166(5):1533-9. doi: 10.1016/S0002-9440(10)62369-3.
85 Interleukin-28A triggers wound healing migration of bladder cancer cells via NF-B-mediated MMP-9 expression inducing the MAPK pathway.Cell Signal. 2012 Sep;24(9):1734-42. doi: 10.1016/j.cellsig.2012.04.013. Epub 2012 Apr 25.
86 Differential Effects of Histone Acetyltransferase GCN5 or PCAF Knockdown on Urothelial Carcinoma Cells.Int J Mol Sci. 2017 Jul 5;18(7):1449. doi: 10.3390/ijms18071449.
87 Comparison of genome-wide DNA methylation in urothelial carcinomas of patients with and without arsenic exposure.Environ Res. 2014 Jan;128:57-63. doi: 10.1016/j.envres.2013.10.006. Epub 2013 Nov 22.
88 High expression of KPNA2 defines poor prognosis in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy.BMC Cancer. 2015 May 9;15:380. doi: 10.1186/s12885-015-1369-8.
89 Transcriptional Analysis of Immunohistochemically Defined Subgroups of Non-Muscle-Invasive Papillary High-Grade Upper Tract Urothelial Carcinoma.Int J Mol Sci. 2019 Jan 29;20(3):570. doi: 10.3390/ijms20030570.
90 Ureteroscopic Management of Large ? cm Upper Tract Urothelial Carcinoma: A Comprehensive 23-Year Experience.Urology. 2018 Nov;121:66-73. doi: 10.1016/j.urology.2018.05.042. Epub 2018 Jun 30.
91 LGALS4 as a Prognostic Factor in Urothelial Carcinoma of Bladder Affects Cell Functions.Technol Cancer Res Treat. 2019 Jan 1;18:1533033819876601. doi: 10.1177/1533033819876601.
92 Ablation of MCM10 using CRISPR/Cas9 restrains the growth and migration of esophageal squamous cell carcinoma cells through inhibition of Akt signaling.Onco Targets Ther. 2018 Jun 6;11:3323-3333. doi: 10.2147/OTT.S157025. eCollection 2018.
93 Analysis of papillary urothelial carcinomas of the bladder with grade heterogeneity: supportive evidence for an early role of CDKN2A deletions in the FGFR3 pathway.Histopathology. 2017 Jan;70(2):281-289. doi: 10.1111/his.13063. Epub 2016 Oct 28.
94 Trivalent arsenicals induce lipid peroxidation, protein carbonylation, and oxidative DNA damage in human urothelial cells.Mutat Res. 2007 Feb 3;615(1-2):75-86. doi: 10.1016/j.mrfmmm.2006.10.003. Epub 2006 Nov 28.
95 MCM10 overexpression implicates adverse prognosis in urothelial carcinoma.Oncotarget. 2016 Nov 22;7(47):77777-77792. doi: 10.18632/oncotarget.12795.
96 Characterization of inflammasome-related genes in urine sediments of patients receiving intravesical BCG therapy.Urol Oncol. 2017 Dec;35(12):674.e19-674.e24. doi: 10.1016/j.urolonc.2017.08.004. Epub 2017 Sep 6.
97 Putative tumour suppressor gene necdin is hypermethylated and mutated in human cancer.Br J Cancer. 2013 Apr 2;108(6):1368-77. doi: 10.1038/bjc.2013.104.
98 Urinary NID2 and TWIST1 methylation to augment conventional urine cytology for the detection of bladder cancer.Cancer Biomark. 2017;18(4):381-387. doi: 10.3233/CBM-160261.
99 Genes involved in differentiation, stem cell renewal, and tumorigenesis are modulated in telomerase-immortalized human urothelial cells.Mol Cancer Res. 2008 Jul;6(7):1154-68. doi: 10.1158/1541-7786.MCR-07-2168.
100 A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria.J Urol. 2012 Sep;188(3):741-7. doi: 10.1016/j.juro.2012.05.003. Epub 2012 Jul 19.
101 PIAS1 is not suitable as a urothelial carcinoma biomarker protein and pharmacological target.PLoS One. 2019 Oct 22;14(10):e0224085. doi: 10.1371/journal.pone.0224085. eCollection 2019.
102 AKT1 E17 K pleckstrin homology domain mutation in urothelial carcinoma.Cancer Genet Cytogenet. 2009 May;191(1):34-7. doi: 10.1016/j.cancergencyto.2009.01.009.
103 Loss of periplakin expression is associated with the tumorigenesis of colorectal carcinoma.Biomed Pharmacother. 2017 Mar;87:366-374. doi: 10.1016/j.biopha.2016.12.103. Epub 2017 Jan 6.
104 Prostate tumor overexpressed 1 expression in invasive urothelial carcinoma.J Cancer Res Clin Oncol. 2016 May;142(5):937-47. doi: 10.1007/s00432-015-2107-y. Epub 2016 Jan 8.
105 Polycomb group oncogene RING1 is over-expressed in non-small cell lung cancer.Pathol Oncol Res. 2014 Jul;20(3):549-56. doi: 10.1007/s12253-013-9727-9. Epub 2014 Jan 11.
106 Overexpression of RNF2 Is an Independent Predictor of Outcome in Patients with Urothelial Carcinoma of the Bladder Undergoing Radical Cystectomy.Sci Rep. 2016 Feb 12;6:20894. doi: 10.1038/srep20894.
107 Infrequent alteration in the p53R2 gene in human transitional cell carcinoma of the urinary tract.Pathobiology. 2004;71(2):103-6. doi: 10.1159/000074424.
108 Urothelial carcinoma of the upper urinary tract diagnosed via FGFR3 mutation detection in urine: a case report.BMC Urol. 2012 Aug 8;12:20. doi: 10.1186/1471-2490-12-20.
109 SH3BGRL3 Protein as a Potential Prognostic Biomarker for Urothelial Carcinoma: A Novel Binding Partner of Epidermal Growth Factor Receptor.Clin Cancer Res. 2015 Dec 15;21(24):5601-11. doi: 10.1158/1078-0432.CCR-14-3308. Epub 2015 Aug 18.
110 Loss of Sh3gl2/endophilin A1 is a common event in urothelial carcinoma that promotes malignant behavior.Neoplasia. 2013 Jul;15(7):749-60. doi: 10.1593/neo.121956.
111 The evolving genomic landscape of urothelial carcinoma.Nat Rev Urol. 2017 Feb 7;14(4):215-229. doi: 10.1038/nrurol.2017.11. Online ahead of print.
112 Microsatellite instability and TARBP2 mutation study in upper urinary tract urothelial carcinoma.Am J Clin Pathol. 2013 Jun;139(6):765-70. doi: 10.1309/AJCPBSLP8XHSWLOW.
113 TGFBI Protein Is Increased in the Urine of Patients with High-Grade Urothelial Carcinomas, and Promotes Cell Proliferation and Migration.Int J Mol Sci. 2019 Sep 11;20(18):4483. doi: 10.3390/ijms20184483.
114 Human TLR gene family members are differentially expressed in patients with urothelial carcinoma of the bladder.Urol Oncol. 2017 Dec;35(12):674.e11-674.e17. doi: 10.1016/j.urolonc.2017.07.029. Epub 2017 Aug 24.
115 Low expression of TMEM67 is a critical predictor of poor prognosis in human urothelial carcinoma of the bladder.Urol Oncol. 2017 Apr;35(4):152.e7-152.e12. doi: 10.1016/j.urolonc.2016.10.014. Epub 2017 Feb 1.
116 A placebo-controlled efficacy study of the intravesical immunomodulators TMX-101 and TMX-202 in an orthotopic bladder cancer rat model.World J Urol. 2018 Nov;36(11):1719-1725. doi: 10.1007/s00345-018-2334-3. Epub 2018 May 16.
117 TNFAIP2 expression induces epithelial-to-mesenchymal transition and confers platinum resistance in urothelial cancer cells.Lab Invest. 2019 Nov;99(11):1702-1713. doi: 10.1038/s41374-019-0285-y. Epub 2019 Jul 1.
118 Sulfatase-1 overexpression indicates poor prognosis in urothelial carcinoma of the urinary bladder and upper tract.Oncotarget. 2017 Jul 18;8(29):47216-47229. doi: 10.18632/oncotarget.17590.